CSL Limited reports strong sales and profit growth

Shares of Australia’ leading biotech firm CSL Limited (ASX: CSL) closed with a 3.7% rise at A$272.80 today as it posted financial results for the full year ended June 2023.

Total revenue for the year at constant currency up 31% to US$13.826 billion, US$2.030 billion of which is attributable to CSL Vifor.

Net profit after tax (NPAT) for the year attributable to members of the parent entity at constant currency is up 8% to US$2.441 billion. NPATA2 for the year attributable to members of the parent entity at constant currency up 20% to US$2.855 billion